EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Laryngopharyngeal cancer: comparative analysis of survival with surgical and non-surgical treatment algorithms

P. I. Mykhailiuk, V. V. Boyko, A. Ya. Lozynskyi, S. S. Tsybran, H. A. Oleksiuk, I. D. Kostyshyn, A. Ye. Kryzhanivska

Pathologia · 30.04.2026 · 23 (1) · 49-55

DOI: 10.14739/2310-1237.2026.1.355248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathologia, online erschienen am 30.04.2026. Verfasst von P. I. Mykhailiuk und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypopharyngeal cancer is one of the most aggressive head and neck malignancies, characterized by late diagnosis and a poor prognosis. Selecting the optimal radical treatment strategy remains a challenging clinical issue, highlighting the need for a comparative analysis of existing methods to improve personalized therapy.

Aim

To conduct a retrospective real-world data analysis and evaluate treatment outcomes in patients with locally advanced stage III and IVa squamous cell hypopharyngeal carcinoma. Materials and methods. A retrospective analysis was conducted on 120 patients with stage III-IVa squamous cell hypopharyngeal carcinoma (2013–2024). Patients were divided into four groups: Group 1 – surgery with adjuvant therapy (n = 11); Group 2 – neoadjuvant chemotherapy (NACT) followed by surgery (n = 20); Group 3 – chemotherapy and radiation therapy (n = 72); Group 4 – chemoradiotherapy (n = 17). Overall survival (Kaplan–Meier method) and recurrence characteristics were evaluated. Multivariate Cox regression analysis was applied to identify independent prognostic factors, adjusting for clinical and morphological characteristics (T stage, N stage, grade G, growth form, age and gender).

Results

The lowest 1-year mortality was recorded in Group 2 (25.0 %) and Group 1 (36.4 %), while in non-surgical groups, it reached 62.5–70.6 %. Group 2 demonstrated the highest 3-year survival rate (65.0 %), significantly exceeding the results of Group 3 (29.1 %) and Group 4 (23.5 %). Recurrence rates were highest in Group 2 (60.0 %). According to multivariate Cox regression analysis, treatment with the NACT + surgery algorithm (Group 2) was associated with improved overall survival compared to the conservative standard (HR = 0.38, p = 0.023), indicating its possible role as a favorable prognostic factor.

Conclusions

Retrospective real-world data analysis demonstrated that treatment algorithms involving a surgical component are associated with higher 3-year overall survival rates (36.4–65.0 %) compared to non-surgical methods (23.5–29.1 %). The strategy of NACT followed by surgery showed the highest survival (65.0 %). The higher recorded recurrence rate in surgical groups (60.0 %) may be related to prolonged patient survival and broader opportunities for effective salvage therapy. However, these findings are associative and require confirmation in prospective studies.

Zitieren

APA

Mykhailiuk, P. I., Boyko, V. V., Lozynskyi, A. Y., Tsybran, S. S., Oleksiuk, H. A., Kostyshyn, I. D., & Kryzhanivska, A. Y. (2026). Laryngopharyngeal cancer: comparative analysis of survival with surgical and non-surgical treatment algorithms. Pathologia, 23(1), 49-55. https://doi.org/10.14739/2310-1237.2026.1.355248

Vancouver

Mykhailiuk PI, Boyko VV, Lozynskyi AY, Tsybran SS, Oleksiuk HA, Kostyshyn ID, et al. Laryngopharyngeal cancer: comparative analysis of survival with surgical and non-surgical treatment algorithms. Pathologia. 2026;23(1):49-55. doi:10.14739/2310-1237.2026.1.355248

BibTeX
@article{Mykhailiuk2026,
  author = {Mykhailiuk, P. I. and Boyko, V. V. and Lozynskyi, A. Ya. and Tsybran, S. S. and Oleksiuk, H. A. and Kostyshyn, I. D. and Kryzhanivska, A. Ye.},
  title = {Laryngopharyngeal cancer: comparative analysis of survival with surgical and non-surgical treatment algorithms},
  journal = {Pathologia},
  year = {2026},
  volume = {23},
  number = {1},
  pages = {49--55},
  doi = {10.14739/2310-1237.2026.1.355248}
}
Kostenlos starten →